Loading organizations...
Loading organizations...
Waltz Health is a technology company.
Waltz Health operates a technology platform designed to empower consumers by helping them identify the most affordable prescription medications. This innovative system establishes a new framework for pricing and reimbursing prescriptions, streamlining the process for individuals to purchase their medicine at reduced costs. It leverages advanced technology to improve overall prescription care accessibility and cost-effectiveness.
The company was founded in 2021 by Mark Thierer and Jonathon Thierer. These industry leaders, bringing decades of combined experience in healthcare and technology, recognized the imperative for a more collaborative and intelligent approach to prescription care. Their founding insight centered on utilizing their extensive knowledge to construct a smarter, more efficient system for the benefit of consumers navigating medication costs.
Waltz Health primarily serves consumers seeking greater transparency and lower prices for their pharmaceutical needs. The company's vision is to continuously empower individuals, ultimately improving the quality of care while simultaneously generating significant savings. It is committed to building a perpetually evolving system that ensures consumers can consistently access necessary medications at the most advantageous prices.
Waltz Health has raised $35.0M across 1 funding round.
Waltz Health has raised $35.0M in total across 1 funding round.
Waltz Health is a Chicago-based digital health technology company founded in 2021 that integrates AI-powered solutions into the pharmacy benefit process to enhance prescription drug affordability and access.[2][3] It builds products like the Marketplace Search application, which provides consumers with transparent drug pricing information, automatically delivering the lowest price at the pharmacy counter via benefits or cash-pay discounts, while filling data gaps for health plans and sponsors.[2] Serving millions across the U.S., including consumers, payers, pharmacies, and retailers, Waltz addresses the pervasive issue of prescription drug costs—impacting nearly 1 in 4 Americans—by partnering across the pharmaceutical supply chain to realign incentives and reduce prices.[2][3] The company has shown strong growth momentum, raising a $35M Series A in partnership with investors like Define Ventures, GV, and Echo Health Ventures, and recently merging with EVERSANA in August 2025 to bolster pharma commercialization capabilities.[1][3]
Waltz Health was founded in 2021 by Mark Thierer, a seasoned executive and former CEO of Catamaran (acquired by OptumRx for $13B), alongside a team with deep expertise in pharmacy benefit managers (PBMs).[2][3] The idea emerged from Thierer's intimate knowledge of the opaque pharmaceutical supply chain, where complex pricing burdens consumers, especially those with chronic conditions, leading to non-compliance and high costs.[3] Early traction came from launching Marketplace Search, an AI-driven tool that empowers users with pricing transparency and has scaled to serve millions nationwide, positioning Waltz as a neutral partner to all supply chain players.[2][3] A pivotal moment was joining the Pharmaceutical Care Management Association (PCMA) in February 2024, affirming its role in PBM innovation, followed by the $35M Series A and the transformative EVERSANA merger.[1][2][3]
Waltz Health stands out in the digital health space through these key strengths:
Waltz Health rides the wave of healthcare price transparency and AI-driven supply chain optimization, amplified by regulatory pushes like the U.S. push for drug pricing reforms and rising consumer demand amid 1-in-4 Americans struggling with med costs.[2][3] Timing is ideal post-2021 founding, aligning with PBM evolution, AI adoption in pharma, and post-pandemic focus on affordability, positioning it amid market forces like chronic disease prevalence and retailer margin pressures.[2][3] By joining PCMA and merging with EVERSANA, Waltz influences the ecosystem as a diversifying PBM innovator, promoting tools that lower costs for 266M+ insured lives while challenging opaque pricing—potentially reshaping how payers and pharmacies deliver value.[1][2]
Post-EVERSANA merger, Waltz is poised to accelerate with enhanced commercialization muscle, rolling out high-cost med solutions and expanding AI tools amid intensifying drug pricing scrutiny.[1][2] Trends like AI personalization in benefits, value-based care, and bipartisan affordability mandates will propel growth, evolving Waltz from a transparency disruptor to a dominant force in rewired pharma access.[2][3] Its supply chain neutrality and expert team signal outsized influence, potentially redefining consumer trust in prescriptions much like it started: by making life-saving drugs truly affordable.
Waltz Health has raised $35.0M in total across 1 funding round.
Waltz Health's investors include GV, 7wire Ventures, Define Ventures, General Catalyst, Oak HC/FT, Optum Ventures, Sapphire Ventures, Slow Ventures, Threshold Ventures, BlueCross BlueShield Venture Partners, Byers Capital, Echo Health Ventures.
Waltz Health has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $35.0M Series A | GV | 7wire Ventures, Define Ventures, General Catalyst, Oak HC/FT, Optum Ventures, Sapphire Ventures, Slow Ventures, Threshold Ventures, BlueCross BlueShield Venture Partners, Byers Capital, Echo Health Ventures, Twine Ventures |